[go: up one dir, main page]

AR108712A1 - (5r)-5-[3-[(3s)-4-(4-cloro-3-metoxi-5-metil-fenil)-3-metil-piperazin-1-il]-3-oxo-propil]-5-metil-imidazolidin-2,4-diona, composiciones farmacéuticas del mismo para el tratamiento de trastornos inflamatorios y osteoartritis - Google Patents

(5r)-5-[3-[(3s)-4-(4-cloro-3-metoxi-5-metil-fenil)-3-metil-piperazin-1-il]-3-oxo-propil]-5-metil-imidazolidin-2,4-diona, composiciones farmacéuticas del mismo para el tratamiento de trastornos inflamatorios y osteoartritis

Info

Publication number
AR108712A1
AR108712A1 ARP170101596A ARP170101596A AR108712A1 AR 108712 A1 AR108712 A1 AR 108712A1 AR P170101596 A ARP170101596 A AR P170101596A AR P170101596 A ARP170101596 A AR P170101596A AR 108712 A1 AR108712 A1 AR 108712A1
Authority
AR
Argentina
Prior art keywords
methyl
propil
metoxi
diona
imidazolidin
Prior art date
Application number
ARP170101596A
Other languages
English (en)
Original Assignee
Galapagos Nv
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv, Servier Lab filed Critical Galapagos Nv
Publication of AR108712A1 publication Critical patent/AR108712A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto de acuerdo con la fórmula (1), o una sal farmacéuticamente aceptable, o un solvato, o una sal farmacéuticamente aceptable de un solvato del mismo; o un metabolito biológicamente activo del mismo.
ARP170101596A 2016-06-09 2017-06-09 (5r)-5-[3-[(3s)-4-(4-cloro-3-metoxi-5-metil-fenil)-3-metil-piperazin-1-il]-3-oxo-propil]-5-metil-imidazolidin-2,4-diona, composiciones farmacéuticas del mismo para el tratamiento de trastornos inflamatorios y osteoartritis AR108712A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1610055.4A GB201610055D0 (en) 2016-06-09 2016-06-09 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis

Publications (1)

Publication Number Publication Date
AR108712A1 true AR108712A1 (es) 2018-09-19

Family

ID=56894696

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101596A AR108712A1 (es) 2016-06-09 2017-06-09 (5r)-5-[3-[(3s)-4-(4-cloro-3-metoxi-5-metil-fenil)-3-metil-piperazin-1-il]-3-oxo-propil]-5-metil-imidazolidin-2,4-diona, composiciones farmacéuticas del mismo para el tratamiento de trastornos inflamatorios y osteoartritis

Country Status (6)

Country Link
US (1) US10829478B2 (es)
EP (1) EP3468955B1 (es)
AR (1) AR108712A1 (es)
GB (1) GB201610055D0 (es)
TW (1) TW201802079A (es)
WO (2) WO2017211666A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230026611A1 (en) * 2019-10-07 2023-01-26 D. E. Shaw Research, Llc ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS
EP3822268A1 (en) 2019-11-15 2021-05-19 Bayer Aktiengesellschaft Substituted hydantoinamides as adamts7 antagonists
EP3822265A1 (en) 2019-11-15 2021-05-19 Bayer AG Substituted hydantoinamides as adamts7 antagonists
CN113754635B (zh) * 2020-06-02 2024-06-21 成都康弘药业集团股份有限公司 稠环类化合物及其制备方法和用途
CN115720578B (zh) * 2020-07-09 2025-06-13 深圳信立泰药业股份有限公司 并三环类衍生物、其制备方法及其在医药上的应用
CN117136051A (zh) * 2021-04-02 2023-11-28 江苏恒瑞医药股份有限公司 Adamts抑制剂的前药、其制备方法和医药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0617948A2 (pt) * 2005-10-28 2011-08-09 Takeda Pharmaceutical composto, pró-droga de um composto, agente farmacêutico, método para inibir uma metaloproteinase de matriz, e, uso de um composto
DK2650310T3 (en) 2012-04-13 2016-09-12 Rottapharm Biotech Srl The anti-ADAMTS-5 antibody, derivatives and uses thereof
AR092971A1 (es) * 2012-10-26 2015-05-06 Lilly Co Eli Inhibidores de agrecanasa
JO3501B1 (ar) * 2014-12-22 2020-07-05 Servier Lab مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام)

Also Published As

Publication number Publication date
WO2017211668A1 (en) 2017-12-14
WO2017211666A1 (en) 2017-12-14
EP3468955A1 (en) 2019-04-17
GB201610055D0 (en) 2016-07-27
US10829478B2 (en) 2020-11-10
US20190315719A1 (en) 2019-10-17
TW201802079A (zh) 2018-01-16
EP3468955B1 (en) 2021-01-06

Similar Documents

Publication Publication Date Title
AR108712A1 (es) (5r)-5-[3-[(3s)-4-(4-cloro-3-metoxi-5-metil-fenil)-3-metil-piperazin-1-il]-3-oxo-propil]-5-metil-imidazolidin-2,4-diona, composiciones farmacéuticas del mismo para el tratamiento de trastornos inflamatorios y osteoartritis
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
NZ780890A (en) Pharmaceutical compositions comprising meloxicam
MX390302B (es) Oxiesteroles y metodos de uso de los mismos
MX384868B (es) Composiciones para tratar atrofia muscular espinal.
MX2020010690A (es) Oxiesteroles y metodos de uso de los mismos.
EA201891489A1 (ru) Фармацевтическая композиция, содержащая аморфный леналидомид и антиоксидант
CR20170411A (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina
MX376062B (es) Agonistas del receptor muscarinico.
EA201691670A1 (ru) Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
MX2016008665A (es) Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo.
CL2017001479A1 (es) Combinación farmacéutica que comprende un agonista selectivo del receptor s1p1
MX2016013801A (es) Moduladores del receptor acoplado a la proteina g 40 (gpr40) de pirrolidina para el tratamiento de enfermedades como la diabetes.
EA202092620A1 (ru) Соли и твердые формы монобактамного антибиотика
AR095032A1 (es) Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo
JOP20190049A1 (ar) مثبطات دوبامين-b-هيدروكسيلاز
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
MX385203B (es) Compuestos y métodos para tratar infecciones bacterianas.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
WO2015001541A3 (en) Pharmaceutical film composition
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
AR110770A1 (es) Moduladores del canal de potasio

Legal Events

Date Code Title Description
FB Suspension of granting procedure